Alfentanil Hydrochloride

證據等級: L5

預測適應症: 0 個

Alfentanil Hydrochloride: From Anesthesia Adjunct to No Repurposing Prediction Available

One-Sentence Summary

Alfentanil Hydrochloride is a short-acting synthetic opioid analgesic primarily used as an anesthetic adjunct for intraoperative analgesia and sedation in monitored care settings. The TxGNN model did not generate any repurposing predictions for this drug in the current run, likely due to incomplete input data (missing DrugBank ID and indication mapping). With critical data gaps in both safety profile and mechanistic annotation, further data collection is required before meaningful repurposing analysis can proceed.

Quick Overview

Item	Content
Original Indication	Short-acting analgesia adjunct in general anesthesia and monitored anesthesia care
Predicted New Indication	— Not available (no TxGNN prediction generated)
TxGNN Prediction Score	— N/A
Evidence Level	L5 — Model prediction not generated; data insufficient
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacological knowledge, Alfentanil Hydrochloride is a 4-anilidopiperidine–class synthetic opioid that acts as a full agonist at the μ-opioid receptor (MOR), producing rapid-onset, short-duration analgesia and sedation. Its ultrashort context-sensitive half-life makes it particularly suited for procedural analgesia and intraoperative use.

No TxGNN repurposing prediction was generated for this drug in the current pipeline run. This is most likely because the DrugBank ID was not resolved (recorded as null), preventing the knowledge graph from mapping Alfentanil to the required node in the drug–disease bipartite network. Without a valid DrugBank anchor, neither KG-based nor deep learning–based predictions can be executed.

Before any repurposing hypothesis can be evaluated, the pipeline must first resolve the DrugBank ID (likely DB00802 — Alfentanil), populate the approved indication text from the NPRA/TFDA product monograph, and re-run the full prediction workflow. Only then will a scientifically grounded evaluation be possible.

Malaysia Market Information

The Evidence Pack confirms one active registration in Malaysia; however, the detailed product fields (authorization number, product name, dosage form, manufacturer, and approved indication text) were returned empty from the regulatory query. The registration record exists but could not be fully retrieved.

Authorization Number	Product Name	Dosage Form	Approved Indication
— (record present, details not retrieved)	—	—	—

Action required: Retrieve the full NPRA product monograph to populate the above fields and confirm the approved indication text.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, and drug–drug interactions) returned as data gaps in this Evidence Pack. Given that Alfentanil is a Schedule II–equivalent controlled opioid, known safety concerns include respiratory depression, CNS depression, bradycardia, chest wall rigidity (at high doses), potential for misuse and dependence, and interactions with CNS depressants (benzodiazepines, propofol, volatile anesthetics, MAOIs). These must be formally documented from the approved product monograph before any repurposing evaluation proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline produced zero repurposing predictions for Alfentanil Hydrochloride because the DrugBank ID could not be resolved, blocking knowledge graph node mapping and all downstream prediction steps. Without predictions, no evidence review, mechanistic analysis, or benefit–risk assessment is possible at this stage.

To proceed, the following is needed:

[Critical — DG001] Download and parse the NPRA/TFDA product monograph PDF to extract approved indication text, key warnings, and contraindications
[Critical — DG002] Confirm and populate the DrugBank ID (expected: DB00802) to enable KG and DL prediction runs
[Required] Populate all empty NPRA license fields (authorization number, product name, dosage form, manufacturer)
[Required] Re-run the full TxGNN pipeline (run_kg_prediction.py, txgnn_model.py) after resolving the above gaps
[Optional] Query DrugBank API for MOA, pharmacodynamics, and drug interaction data to support mechanistic analysis once predictions are available

⚠️ Disclaimer: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application. This evaluation reflects data available as of 2026-04-04.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.